Table 1.
Patient demographics and disease characteristics
| N patients treated (%) | CEP-9722 dose level (mg/day) | Total | ||||
|---|---|---|---|---|---|---|
| 150 3 |
300 6 |
500 3 |
750 11 |
1,000 3 |
26 | |
| Age in years, mean ± SD | 55.3 ± 11.72 | 53.7 ± 12.91 | 52.3 ± 7.23 | 50.6 ± 15.10 | 57.0 ± 7.94 | 52.8 ± 12.24 |
| Gender | ||||||
| Female | 3 (100) | 4 (67) | 2 (67) | 7 (64) | 2 (67) | 18 (69) |
| Male | 0 | 2 (33) | 1 (33) | 4 (36) | 1 (33) | 8 (31) |
| Smoking status/medications affecting gastric pH | ||||||
| Smoker | 0 | 4 (67) | 0 | 2 (18) | 1 (33) | 7 (27) |
| Nonsmoker | 3 (100) | 2 (33) | 3 (100) | 9 (82) | 2 (67) | 19 (73) |
| Primary cancer | ||||||
|
Breast Ovarian |
2 (67) 0 |
1 (17) 1 (17) |
0 0 |
4 (36) 2 (18) |
0 1 (33) |
7 (27) 4 (15) |
| Colorectal | 0 | 0 | 1 (33) | 1 (9) | 0 | 2 (8) |
| Othera | 1 (33) | 4 (67) | 2 (67) | 4 (36) | 2 (67) | 13 (50) |
| ECOG status | ||||||
| 0 | 2 (67) | 2 (33) | 2 (67) | 4 (36) | 1 (33) | 11 (42) |
| 1 | 1 (33) | 4 (67) | 1 (33) | 7 (64) | 1 (33) | 14 (54) |
| 2 | 0 | 0 | 0 | 0 | 1 (33) | 1 (4) |
| Prior anticancer radiotherapy | 3 (100) | 2 (33) | 1 (33) | 7 (64) | 0 | 13 (50) |
| Prior systemic anticancer chemotherapy | 3 (100) | 6 (100) | 3 (100) | 11 (100) | 3 (100) | 26 (100) |
ECOG Eastern Cooperative Oncology Group, SD standard deviation
aOther includes 1 each: abdominal/pelvic sarcoma, adenocarcinoma of the jejunum, atypical carcinoid cancer, cervix uteri cancer, cholangiocarcinoma, external ear cancer, gallbladder cancer, esophageal cancer, lung cancer, melanoma, prostate cancer, stomach cancer, and urothelial carcinoma